Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial
Journal of Diabetes Investigation · 2026
DOI: 10.1111/jdi.70330 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Diabetes Investigation, 2026. Verfasst von Yoko Takatsuna und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Chiba Rosai Hospital, Ichihara, Japan. Hauptthemen laut MEDLINE: Macular Edema, Diabetic Retinopathy, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Taisho Toyama Pharmaceutical Company.
Abstract (Originalsprache)
Aims
To investigate the potential of sodium–glucose cotransporter 2 inhibitors (SGLT2i) as a less invasive treatment option for mild diabetic macular edema (DMO) via post hoc subgroup analysis. Previous findings were derived exclusively from observational studies, and no interventional trials based on protocol‐defined criteria had been conducted. Materials and Methods Based on the COMET trial data, this post hoc analysis targeted mild DME cases, defined by baseline central retinal thickness (CRT) ≤375 μm and best‐corrected visual acuity (BCVA) ≤0.155 (logMAR). Patients were randomized to SGLT2i (luseogliflozin) or sulfonylurea (SU, glimepiride) groups. Mild subgroups were compared with the corresponding non‐mild cases. The primary outcome was the 48‐week frequency of intravitreal ranibizumab injections (IVRs).
Results
In the CRT ≤375 μm subgroup, IVR frequency was significantly lower with SGLT2i vs SU (mean 0.5 ± 1.0 vs 4.3 ± 0.8; P = 0.005, adjusted ancova . Cohen's d of 2.1). The cumulative mean number of IVRs was significantly lower in the SGLT2i group than in the SU group ( P = 0.004, hazard ratio 0.29, 95% confidence interval 0.12–0.67). In the BCVA ≤ 0.155 subgroup, whose mean CRT exceeded 400 μm, no significant difference in IVR frequency was observed between the SGLT2i‐treated and SU‐treated patients. In addition, no intergroup differences were found in patients outside the mild subgroups.
Conclusions
In this exploratory analysis, SGLT2 inhibition was associated with fewer intravitreal injections in patients meeting the CRT‐based mild criteria. These findings are hypothesis‐generating and warrant confirmation in future prospective studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Chiba Rosai Hospital, Ichihara, Japan.
- Department of Ophthalmology and Vision Science, Chiba University Graduate School of Medicine, Chiba, Japan.
- Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Kimitsu Chuo Hospital, Kisarazu, Japan.
- Department of Endocrinology, Haematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.
- Department of Nutrition and Metabolic Medicine, Center for Preventive Medical Sciences, Chiba University, Chiba, Japan.
ORCID-Profile: Yoko Takatsuna, Masaya Koshizaka, Tomoaki Tatsumi
Förderung
- Taisho Toyama Pharmaceutical Company
Zitieren
APA
Takatsuna, Y., Ishibashi, R., Koshizaka, M., Tatsumi, T., Baba, T., Yamamoto, S., & Yokote, K. (2026). Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.70330
Vancouver
Takatsuna Y, Ishibashi R, Koshizaka M, Tatsumi T, Baba T, Yamamoto S, et al. Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial. Journal of Diabetes Investigation. 2026. doi:10.1111/jdi.70330
BibTeX
@article{Takatsuna2026,
author = {Takatsuna, Yoko and Ishibashi, Ryoichi and Koshizaka, Masaya and Tatsumi, Tomoaki and Baba, Takayuki and Yamamoto, Shuichi and Yokote, Koutaro},
title = {Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial},
journal = {Journal of Diabetes Investigation},
year = {2026},
doi = {10.1111/jdi.70330}
}
EUVIMED